MORE THAN JUST PATIENT’S
European association taking the interests of European pALS
EupALS is an European association taking the interests of European pALS (ALS patients) to heart. We thus want to create equal rights for all the European pALS and provide better access to research and information about it.
Subscribe to our newsletter
NEWS
-
EMA announcement positive CHMP opinion for Biogen Tofersen (Qualsody)
23 February 2024 New treatment for rare motor neurone disease recommended for approval EMA has recommended granting a marketing authorisation in the European Union for a new therapy for the… More >>
-
EUpALS in Lancet Neurology editorial November 2023
Speeding up research to improve the lives of people with ALS Advances in research over the past few years have provided a greater understanding of the pathophysiology, genetics, and risk… More >>
MISSION
Aiming to unite all the European ALS associations…
… to fight harder together on a European scale
Stand up for the rights of all the European pALS
Create awareness on a European scale
Improve access to & information about research
Create the same rules for ALS research across Europe
ALS RESEARCH NEWS
Checkout the most recent Articles And Insights on ALS Research
-
Novartis ASTRALS trial with VHB937 in ALS fully enrolled
Community Statement:Enrollment complete for Novartis Phase 2 (ASTRALS) Clinical Trial in amyotrophic lateral sclerosis (ALS) More >>
-
Community Update:First Participant Enrolled in the PREVAiLS Phase 3 ALS Study
March 30, 2026 Dear ALS community, We are delighted to share that a new global, pivotal Phase 3 clinical trial, called PREVAiLS, studying the investigational drug pridopidine, has enrolled its… More >>
-
Ferrer and Prilenia Announce First Participant Enrolled inthe “PREVAiLS” Phase 3 Study of Pridopidine in ALS
March 30, 2026 PREVAiLS is a pivotal, global, 500-participant Phase 3 study to evaluate efficacy and safety of pridopidine, an investigational drug, in slowing ALS progression (ALSFRS-R) in early, rapidly… More >>
-
Additional Phase 2 Data of AL-S Pharma Lead Program with AP-101 in ALS
March 19 2026 Additional Phase 2 Data of AL-S Pharma’s Lead Program AP-101 Further Demonstrate Clinically Meaningful Disease Modification and Prolonged Survival in ALS Results supported by key neuroaxonal injury… More >>